DNA methylation in breast and colorectal cancers

Modern Pathology

Volumn 20, Issue 7, 2007, Pages 711-721

  Agrawal, Anshu ^a   Murphy, Richard F ^a   Agrawal, Devendra K ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Chromosomal stability; Colorectal cancer; DNA methylation; Hypermethylation; Hypomethylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AZACITIDINE; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CAFFEIC ACID; CHLOROGENIC ACID; CHOLINE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; FOLIC ACID; GLUCURONOSYLTRANSFERASE; METHIONINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MYOD PROTEIN; PROTEIN; PROTEIN MLH1; PROTEIN MLH2; SELENIUM; TRICHOSTATIN A; UNCLASSIFIED DRUG; ZEBULARINE; ZINC;

AGING; ALCOHOL CONSUMPTION; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; BREAST DUCT CARCINOMA IN SITU; CANCER PREVENTION; CANCER RISK; CARCINOMA IN SITU; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; CPG ISLAND; DIAGNOSTIC VALUE; DIETARY FIBER; DIETARY INTAKE; DISEASE MARKER; DNA HYPERMETHYLATION; DNA HYPOMETHYLATION; DNA METHYLATION; DNA MICROARRAY; DNA SEQUENCE; DRUG MECHANISM; DRUG POTENTIATION; FAMILIAL CANCER; FAT INTAKE; FRUIT; GENE EXPRESSION; GENE SILENCING; GENETIC RISK; HIGH RISK PATIENT; HUMAN; LEUKEMIA; METASTASIS; MICROSATELLITE INSTABILITY; MONOTHERAPY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE; VEGETABLE; VEGETARIAN DIET;

EID: 34250620891     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800822     Document Type: Review

References (139)

1. Nephew KP, Huang TH. Epigenetic gene silencing in cancer and progression. Cancer Lett 2003;190:125-133.
2. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-116.
3. Perez-Plasencia C, Duenas-Gonzalez A. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy? Mol Cancer 2006;5:27.
4. Kim YI. Nutritional epigenetics: impact of folate deficiency on DNA methylation and colon cancer susceptibility. J Nutr 2005;135:2703-2709.
5. Laird PW, Jaenisch R. The role of DNA methylation in cancer genetic and epigenetic. Annu Rev Genet 1996;30:441-464.
6. Feltus FA, Lee EK, Costello JF, et al. DNA motifs associated with aberrant CpG island methylation. Genomics 2006;5:572-579.
7. Vertino PM, Yen RW, Gao J, et al. De novo methylation of CpG island sequences in human fibroblast overexpressing DNA cytosine-5- methyltransferase. Mol Cell Biol 1996;16:4555-4565.
8. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract 2005;2:S4-S11.
9. Bird A. DNA methylation patterns epigenetic memory. Genes Dev 2002;16:6-21.
10. Dunn BK. Hypomethylation: one side of a larger picture. Ann NY Acad Sci 2003;983:28-42.
11. Farrell WE. Epigenetic mechanisms of tumorigenesis. Horm Metab Res 2005;37:361-368.
12. Antequera F, Bird A. Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci USA 1993;90:11995-11999.
13. Ross SA. Diet and DNA methylation interactions in cancer prevention. Ann NY Acad Sci 2003;983:197-207.
14. Brenner C, Fuks F. DNA methyltransferases: facts, clue, mysteries. Curr Top Microbiol Immunol 2006;301:45-66.
15. Gopisetty G, Ramachandran K, Singal R. DNA methylation and apoptosis. Mol Immunol 2006;43:1729-1740.
16. Singal R, Ginder GD. DNA methylation. Blood 1999;93:4059-4070.
17. Agoston AT, Argani P, Yegnasubramanian S, et al. Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem 2005;280:18302-18310.
18. Chen T, Li E. Establishment and maintenance of DNA methylation patterns in mammals. Curr Top Microbiol Immunol 2006;301:179-201.
19. Jaenisch R. DNA methylation and imprinting: why bother? Trends Genet 1997;13:323-329.
20. Rodenhiser D, Mann M. Epigenetics and human disease: translating basic biology into clinical applications. CMAJ 2006;174:341-348.
21. Robertson KD, Ait-Si-Ali S, Yokochil T, et al. DNMT1 forms a complex with Rb, E2F1, and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 2000;25:338-342.
22. Szyf M. The DNA methylation machinery as a therapeutic target. Curr Drug Targets 2000;1:101-118.
23. Eads CA, Danenberg KD, Kawakami K, et al. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 1999;59:2302-2306.
24. Rhee I, Jair KW, Yen RW, et al. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 2000;404:1003-1007.
25. Li E, Beard C, Forster AC, et al. DNA methylation, genomic imprinting, and mammalian development. Cold Spring Harb Symp Quant Biol 1993;58:297-305.
26. De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol 2004;24:4781-4790.
27. Eden A, Gaudet F, Waghmare A, et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003;300:455.
28. Richardson BC. Role of DNA methylation in the regulation of cell function: autoimmunity, aging and cancer. J Nutr 2002;132:2401S-2405S.
29. Waterland RA. Assessing the effects of high methionine intake on DNA methylation. J Nutr 2006;136:1706S-1710S.
30. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumors. J Pathol 2002;196:1-7.
31. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428.
32. Baylin SB, Herman JG, Graff JR. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-196.
33. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-167.
34. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-3229.
35. Balch C, Montgomery JS, Paik HI. New anti-cancer strategies: epigenetic therapies and biomarkers. Front Biosci 2005;10:1897-1931.
36. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
37. Sadri R, Hornsby PJ. Rapid analysis of DNA methylation using new restriction enzyme sites created by bisulfite modification. Nucleic Acids Res 1996;24:5058-5059.
38. Ogino S, Brahmandam M, Kawasaki T, et al. Combined analysis of COX-2and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 2006;8:458-464.
39. Wojdacz TK, Hansen LL. Techniques used in studies of age-related DNA methylation changes. Ann NY Acad Sci 2006;1067:479-487.
40. Tryndyak V, Kovalchuk O, Pogribyny IP. Identification of differentially methylated sites within unmethylated DNA domains in normal and cancer cells. Anal Biochem 2006;356:202-207.
41. Rauch T, Pfeifer GP. Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated-CpG islands in cancer. Lab Invest 2005;85:1172-1180.
42. Rauch T, Li H, Wu X, et al. MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res 2006;66:7939-7947.
43. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997;25:2532-2534.
44. Ho SM, Tang WY. Techniques used in studies of epigenetic dysregulation due to aberrant DNA methylation: an emphasis of fetal-based adult diseases. Reprod Toxicol 2007, Jan 19 [E-pub ahead of print].
45. Ibrahim AE, Thorne NP, Baird K, et al. MMASS: an optimized array-based method for assessing CpG island methylation. Nucleic Acids Res 2006;34:e136.
46. Chen C-M, Chen H-L, Hsiau TH-C, et al. Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes. Am J Pathol 2003;163:37-45.
47. Ballestar E, Paz MF, Valle L, et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 2003;22:6335-6345.
48. Bastian PJ, Yegnasubramanian S, Palapattu GS, et al. Molecular biomarker in prostate cancer: the role of Cpg island hypermethylation. Euro Urol 2004;46:698-708.
49. Schmutte C, Jones PA. Involvement of DNA methylation in human carcinogenesis. Biol Chem 1998;379:377-388.
50. Salozhin SV, Prokhorchuk EB, Geogiev GP. Methylation of DNA - one of the major epigenetic markers. Biochem 2005;70:525-532.
51. Costello JF, Plass C. Methylation matters. J Med Genet 2001;38:285-303.
52. Jackson K, Yu MC, Arakwa K, et al. DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther 2004;12:1225-1231.
53. Chekhun VF, Kulik GI, Yurchenko OV, et al. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett 2006;231:87-93.
54. Szyf M, Pakneshan P, Rabbani SA. DNA methylation and breast cancer. Biochem Pharmacol 2004;68:1187-1197.
55. Ross JS, Linette GP, Stec J, et al. Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn 2003;3:573-585.
56. Wischnewski F, Pantel K, Schwarzenback H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006;4:339-349.
57. Narayan A, Ji W, Zhang X-Y, et al. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer 1998;77:833-838.
58. Yang X, Yan L, Davidson NE. DNA methylation in breast cancer. Endocr Relat Cancer 2001;8:115-127.
59. Miyamoto K, Fukutomi T, Akashi-Tanaka S, et al. Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer 2005;116:407-414.
60. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, et al. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006;8:R38.
61. Caldeira JRF, Prando EC, Quevedo FC, et al. CDH1 promotor hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer 2006;6:48.
62. Oshiro MM, Kim LJ, Wozhiak RJ, et al. Epigenetics silencing of DSC3 is a common event in human breast cancer. Breast Cancer Res 2005;7:R669-R680.
63. Fackler MJ, McVeigh M, Evron E, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, cyclin D2 and twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003;107:970-975.
64. Prasad GL, Valverius EM, McDuffie E, et al. Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be downregulated in neoplastic mammary cells. Cell Growth Differ 1992;3:507-513.
65. Pampalakis G, Sotiropoulou G. Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer. Biol Chem 2006;387:773-782.
66. Sidiropoulos M, Pampalakis G, Sotiropoulou G, et al. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian, and prostate cancers. Tumor Biol 2005;26:324-336.
67. Takahashi Y, Miyoshi Y, Takahata C, et al. Downregulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005;11:1380-1385.
68. Fenton H, Carlile B, Montgomery EA, et al. LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol 2006;14:146-153.
69. Esteller M. Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 2000;36:2294-2300.
70. Hesson L, Dallol A, Minna JD, et al. NORE1A, a homologue of RASSF1A tumor suppressor gene is inactivated in human cancer. Oncogene 2003;22:947-954.
71. Silva J, Silva JM, Dominguez G, et al. Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J Path 2003;199:289-297.
72. Kobatake T, Yano M, Toyooka S, et al. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol Rep 2004;12:1087-1092.
73. Cheng CK, Chow LWC, Loo WTY, et al. The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. Cancer Res 2005;65:8646-8654.
74. Lau QC, Raja E, Salto-Tellez M, et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 2006;66:6512-6520.
75. Levine JJ, Stimson-Crider KM, Vertino PM. Effects of methylation on expression of TMS/ASC in human breast cancer cells. Oncogene 2003;22:3475-3488.
76. Van Zhee KJ, Calvano JE, Bisogna M. Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene 1998;16:2723-2727.
77. Elstrodt F, Hollestelle A, Nagel JHA, et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 2006;66:41-45.
78. Droufakou S, Deshmane V, Roylance R, et al. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001;92:404-408.
79. Saario D, Moreno-Bueno G, Hardisson D, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 2003;106:208-215.
80. Lostumbo A, Mehta D, Setty S, et al. Flow cytometry: a new approach for the molecular profiling of breast cancer. Exp Mol Pathol 2006;80:46-53.
81. Laird PW. The power and the promise of DNA methylation markers. Nature Rev Cancer 2003;3:253-266.
82. Evron E, Dooley WC, Umbricht CB, et al. Detection of breast cancer cells in ductal lavage fluid by methlyation-specific PCR. Lancet 2001;357:1335-1336.
83. Dua RS, Isacke CM, Gui GPH. The intraductal approach to breast cancer biomarker discovery. J Clin Oncol 2006;24:1209-1216.
84. Fackler MJ, Malone K, Zhang Z, et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 2006;12:3306-3310.
85. Hoque MO, Febg O, Toure P, et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 24;2006:4262-4269.
86. Munot K, Bell SM, Lane S, et al. Pattern of expression of genes linked to epigenetic silencing in human breast cancer. Hum Pathol 2006;37:989-999.
87. Girault I, Tozlu S, Lidereau R, et al. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 2003;9:4415-4422.
88. Jubb AM, Quirke P, Oates AJ. DNA methylation, a biomarker for colorectal cancer: implications for screening and pathological utility. Ann NY Acad Sci 2003;983:251-267.
89. Grady WM. Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans 2005;33:684-688.
90. Shames DS, Minna JD, Gazdar AF. DNA methylation in health, disease, and cancer. Curr Mol Med 2007;7:85-102.
91. Bariol C, Suter C, Cheong K, et al. The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am J Pathol 2003;162:1361-1371.
92. Kennedy EP, Hamilton SR. Genetics of colorectal cancer. Semin Surg Oncol 1998;15:126-130.
93. Ye C, Shrubsole MJ, Cai Q, et al. Promoter hypermethylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas. Oncol Rep 2006;16:429-435.
94. Esteller M. CpG island methylation and histone modifications: biology and clinical significance. Ernst Schering Res Found Workshop 2006a;57:115-126.
95. Wynter CV, Kambara T, Walsh MD, et al. DNA methylation patterns in adenomas from FAP, multiple adenoma and sporadic colorectal carcinoma patients. Int J Cancer 2006;118:907-915.
96. Xu XL, Yu J, Zhang HY, et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 2004;10:341-354.
97. Gagnon JF, Bernard O, Villeneuve L, et al. Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin Cancer Res 2006;12:1850-1858.
98. Shu J, Jelinek J, Chang H, et al. Silencing of bidrectional promoters by DNA methylation in tumorigenesis. Cancer Res 2006;66:5077-5084.
99. Ogino S, Kawasaki T, Kirkner GJ, et al. Downregulation of p21 (CDKNIA/CIPI) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Path 2006;210:147-154.
100. Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002;416:552-556.
101. Akiyama Y, Watkins N, Suzuki H, et al. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biochem 2003;23:8429-8439.
102. Liu L, Zhang J, Bates S, et al. A methylation profile of in vitro immortalized human cell lines. Int J Oncol 2005;26:275-285.
103. Kawakami K, Ruszkiewicz A, Bennett G, et al. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer 2006;94:593-598.
104. Bachman KE, Park BH, Rajagopalan H, et al. Histone modifications and silencing prior to DNA Methylation of a tumor suppressor gene. Cancer Cell 2003;3:89-95.
105. Goebel B, Muller H, Reimer T, et al. Gene methylation data - a new challenge for bioinformaticians? Methods Inf Med 2005;44:516-519.
106. Dickinson RE, Dallol A, Bieche I, et al. Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers. Br J Cancer 2004;91:2071-2078.
107. Okochi-Takada E, Nakazawa K, Wakabayashi M, et al. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer 2006;119:1338-1344.
108. Vousden KH. p53: death star. Cell 2000;103:691-694.
109. Ahuja N, Li Q, Mohan AL, et al. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998;58:5489-5494.
110. Ting AH, Jair K, Schuebel KE, et al. Differential requirement for DNA methyltransferase 1 in maintaining human cancer cell gene promoter hypermethylation. Cancer Res 2006;66:729-735.
111. Jair KW, Bachman KE, Suzuki H, et al. De novo CpG island methylation in human cancer cells. Cancer Res 2006;66:682-692.
112. Jass JR, Walsh MD, Barker M, et al. Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability. Eur J Cancer 2002;38:858-866.
113. Ulrich CM. Nutrigenetics in cancer research - folate metabolism and colorectal cancer. J Nutr 2005;135:2698-2701.
114. Anacleto C, Leopoldino AM, Rossi B, et al. Colorectal cancer 'methylator phenotype': fact or artifact? Neoplasia 2005;7:331-335.
115. Gazzoli I, Loda M, Garber J, et al. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the hMLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res 2002;62:3925-3928.
116. McGivern A, Wynter CVA, Whitehall VLJ, et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 2004;3:101-107.
117. Davis AJ, Gelmon KA, Siu LL. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continueous infusion every 4 weeks. Invest New Drugs 2003;21:85-97.
118. Siedlecki P, Boy RG, Musch T, et al. Discovery of two novel, small-molecule inhibitors of DNA methylation. J Med Chem 2006;49:678-683.
119. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
120. Stresemann C, Brueckner B, Musch T, et al. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 2006;66:2794-2800.
121. Jones P. Effects of 5-azacytidine and its 2′-deoxyderivative on cell differentiation and DNA methylation. Pharmacol Ther 1985;28:17-27.
122. Fahrner JA, Eguchi S, Herman JG, et al. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002;62:7213-7218.
123. Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol 2000;183:145-154.
124. Bovenzi V, Le NL, Cote S, et al. DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2′-CdR. Anticancer Drugs 1999;10:471-476.
125. Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol 2005;17:55-60.
126. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2006b;94:176-183.
127. Hurtubise A, Momparler RL. Effect of histone deactylase inhibitor LAQ824 on antineoplastic action of 5-aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother Pharmacol 2006;58:618-625.
128. Jacobs MM. Diet, nutrition and cancer research: an overview. Nutr Today 1993;27:19-23.
129. Dreosti IE. Nutrition, cancer, and aging. Ann NY Acad Sci 1998;854:371-377.
130. Gerber B, Muller H, Reimer T, et al. Nutrition and lifestyle factors on the risk of developing breast cancer. Breast Cancer Res Treat 2003;79:265-276.
131. Geisel J, Schorr H, Bodis M, et al. The vegetarian lifestyle and DNA methylation. Clin Chem Lab Med 2005;43:1164-1169.
132. Duthie SJ, Narayanan S, Brand GM, et al. Impact of folate deficiency on DNA stability. J Nutr 2002;132:2444S-2449S.
133. Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr 2002;132:2350S-23505.
134. Lee WJ, Shim JY, Zhu BT. Mechanisms of inhibition of DNA methyltransferases by tea catechins and bio flavonoids. Mol Pharmacol 2005;68:1018-1030.
135. Lee WJ, Zhu BT. Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 2006;27:269-277.
136. Catania J, Fairweather DS. DNA methylation and cellular aging. Mutat Res 1991;256:283-293.
137. Richardson B, Yung R. Role of DNA methylation in the regulation of cell function. J Lab Clin Med 1999;134:333-340.
138. Issa JP. Aging, DNA methylation and cancer. Crit Rev Onco Hematol 1999;32:31-43.
139. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168-174.